Kuwait’s Minister of Health, Dr. Ahmed Al-Awadhi, has issued a ministerial decision to reduce the price of the diabetes medication Tirzepatide (marketed as Mounjaro) across all its available strengths. The drug, delivered via prefilled injection pens, is included in the updated pricing list outlined in Ministerial Resolution No. 74 of 2023.
The Ministry of Health confirmed that the price cut amounts to a 30% reduction from the current cost, making it the lowest in the region. The decision aims to ease the financial burden on patients and will come into effect three months after publication in the Official Gazette, giving the private healthcare sector adequate time for implementation.Stay updated on Kuwait’s latest news and job openings by following our WhatsApp channel!https://whatsapp.com/channel/0029VaCkXo25q08jnKrRwo27
Tirzepatide is recognized as one of the latest breakthroughs in diabetes treatment. It helps manage blood sugar levels and supports weight loss, offering dual benefits for individuals with type 2 diabetes. It belongs to a new class of medications known as dual GLP-1 and GIP receptor agonists and is administered once weekly via an easy-to-use prefilled pen, encouraging better adherence and improved health outcomes.
The Ministry emphasized that the move aligns with Kuwait’s strategy to enhance access to innovative therapies, standardize drug pricing with international benchmarks, and support long-term treatment sustainability for chronic conditions. It also reinforces the Ministry’s commitment to raising healthcare standards, reducing diabetes complications, and boosting the overall efficiency of the national healthcare system.
